Introduction: Limited data exist comparing dasatinib with imatinib in clinical practice. This study assessed real-world outcomes associated with first-line (1L) dasatinib or imatinib treatment of chronic myeloid leukemia (CML).
Patients And Methods: This retrospective, observational, United States multisite cohort study analyzed electronic medical record data from adults with Philadelphia chromosome-positive (Ph+) CML in the chronic phase (CML-CP) after 1L dasatinib or imatinib between January 2014 and September 2018. Rates of and times to major molecular response (MMR) and deep molecular response (DMR) were assessed overall and in subgroups (low vs. intermediate/high risk, aged <65 vs. ≥65 years, low/normal vs. high body mass index [BMI]).
Results: The dasatinib cohort (n = 309) experienced higher rates of MMR (n = 304, 79% vs. 65%, P < .001) and DMR (44% vs. 25%, P < .001) vs. the imatinib cohort with shorter median times to MMR (11.9 vs. 14.7 months, P < .001) and DMR (30.3 vs. 66.1 months, P < .001). Patients with intermediate-/high-risk disease and those aged <65 years had higher MMR and DMR rates and achieved response earlier with dasatinib (P < .01). Patients with low-risk disease treated with dasatinib had higher rates of DMR (60% vs. 32%, P = .01). Across BMI strata, rates of MMR and DMR were higher with dasatinib (P < .05).
Conclusions: Patients with CML-CP treated with 1L dasatinib achieved higher rates of, with shorter times to, MMR and DMR versus 1L imatinib. These clinically meaningful improvements were observed across subgroups.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clml.2023.10.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Gastrointestinal stromal tumors mimicking as gynecological tumors-A case series.
J Family Med Prim Care
December 2024
Department of Obstetrics and Gynecology, Rajendra Institute of Medical Sciences, Ranchi, Jharkhand, India.
Gastrointestinal stromal tumors (GISTs) are rare mesenchymal tumors that arise from interstitial cells of Cajal. Due to vague presentation, location and confusing imaging studies, they tend to mimic gynaecological tumors. They usually diagnosed intra-operative and histopathology followed by tumor specific receptors such as KIT, CD34, CD 117 and DOG 1 are mainstay of diagnosis of GIST.
View Article and Find Full Text PDFAsciminib resistance of a new BCR::ABL1 p.I293_K294insSSLRD mutant detected in a Ph + ALL patient.
Ann Hematol
January 2025
Univ. Bordeaux, INSERM, BRIC, U1312, Bordeaux, France.
Chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia patients largely benefit from an expanding tyrosine kinase inhibitors (TKIs) toolbox that has improved the outcome of both diseases. However, TKI success is continuously challenged by mutation-driven acquired resistance and therefore, close monitoring of clonal genetic diversity is necessary to ensure proper clinical management and adequate response to treatment. Here, we report the case of a ponatinib-resistant Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) patient harboring a BCR::ABL1 p.
View Article and Find Full Text PDFPaeoniflorin sensitizes imatinib mesylate-resistant chronic myeloid leukemia cells via the inhibition of Cyr61 production.
Anticancer Drugs
January 2025
Department of Laboratory Medicine, Fujian Medical University Union Hospital, Fuzhou, China.
Imatinib mesylate (IM) is a first-line therapy for chronic myeloid leukemia (CML) and exhibits good therapeutic effects, but not in all patients with CML owing to drug resistance. Our previous study showed that Cyr61 plays a key role in IM resistance in CML cells. Paeoniflorin (PF) is a bioactive compound isolated from the traditional Chinese medicine Paeonia lactiflora Pall that displays anticancer activity.
View Article and Find Full Text PDFAssessing endothelial cytotoxicity induced by tyrosine kinase inhibitors: insights from Raman and fluorescence imaging.
Analyst
January 2025
Jagiellonian University, Faculty of Chemistry, Department of Chemical Physics, Gronostajowa 2 St, 30-387 Krakow, Poland.
Since their approval, tyrosine kinase inhibitors (TKIs) have been widely used in antitumor therapy for chronic myeloblastic leukemia. Despite being approved by the FDA in 2001 to treat a rare cancer called chronic myeloid leukemia (CML), imatinib and other TKIs remain subjects of research for several reasons, such as their long-term effects, resistance, or molecular mechanisms. This study uses Raman and fluorescence imaging to investigate the cytotoxic effects of two TKIs, imatinib and dasatinib, on human aortic endothelial cells (HAECs).
View Article and Find Full Text PDFCost-Effectiveness of Frontline TKI Strategies for Chronic Myeloid Leukemia Patients: in Pursuit of Treatment-Free Remission and Dose Reduction.
Value Health
December 2024
Medip Analytics, Netherlands, Gelderland, Nijmegen; Department of Medical Imaging, Radboud University Medical Center, Netherlands, Gelderland, Nijmegen.
Objectives: Chronic myeloid leukemia (CML) management now includes dose-reduction (DR) and treatment-free remission (TFR). Evaluating cost-effectiveness of lifelong-prescribed expensive tyrosine kinase inhibitors (TKIs) for CML is crucial. Prior cost-effectiveness evaluations state that imatinib is the favorable frontline TKI.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!